ArticleKidney international reports2024
Long-Term Kidney Outcome of Lupus Nephritis by Renal Response Status.
Article in Kidney international reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Rituximab as Rescue or Add-On Therapy for Relapsing or Refractory Lupus Nephritis: A Systematic Review and Meta-Analysis.Clinical and translational science · 2026Pooled it
- Review
- Article
- Renal Response Status and Long-Term Kidney Outcomes in Childhood-Onset Lupus Nephritis.Kidney international reports · 2026Article
- The potential for identification of biomarkers specific for childhood-onset lupus nephritis using bioinformatics.Pediatric research · 2025Review
- Early Renal Remission Is Associated with Increased Likelihood of Subsequent Remission in Lupus Nephritis: Single-Centre Observational Study in Australia.International journal of molecular sciences · 2025Observational
- Lupus nephritis.Nature reviews. Disease primers · 2025Review
- Childhood-onset lupus nephritis: long-term outcomes and their predictors.Pediatric nephrology (Berlin, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Limited evidence exists that clinical trial treatment response criteria predict long-term outcomes in Asian patients with lupus nephritis (LN). Methods: This retrospective analysis of prospectively collected data from the Hong Kong Queen Mary Hospital Cohort categorized adults with biopsy-proven LN (Class III, IV, V, or mixed [III ± V, IV ± V]) after standard treatment for 2 years postbiopsy and immunosuppression induction according to modified primary efficacy renal response (mPERR: estimated glomerular filtration rate [eGFR] ≥ 60 ml/min per 1.73 m Results: Of the 176 Chinese patients, 64.2% achieved mPERR and 43.8% achieved mCRR at 2 years postbiopsy. After mean follow-up of 15.3 years, significantly higher proportions of mPERR and mCRR responders versus nonresponders achieved long-term kidney survival (mPERR: 85.8% vs. 71.4%; Conclusion: In Chinese patients with LN, mPERR and mCRR at 2 years postbiopsy predict superior long-term kidney outcomes and lower CKD progression risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.